Improving brand adherence rates requires pharma marketers to have access to two growing bodies of knowledge. These are: 1) carefully evaluated evidence for what can improve brand revenue, and 2) informed forecasts of trends.
Improving brand adherence rates requires pharma marketers to have access to two growing bodies of knowledge. These are: 1) carefully evaluated evidence for what can improve brand revenue, and 2) informed forecasts of trends.
Patient Adherence and Access Summit
June 17–18, 2014
Philadelphia, Pennsylvania
RELATED
- Changing the DNA of Pharma Patient Adherence Programs
- Why Patient Adherence is a Policy Issue
- The First and Last Word on Medication Adherence: Keep Trying
MORE IN PATIENT ADHERENCE & ACCESS
How can this knowledge help? Many recent industry programs have achieved only a 1-3% increase in adherence, and ROIs of less than 3. To realize results of 20%+ and ROIs above 3/1, critical appraisal of the past and direction to probable futures are needed (several pharma companies have achieved 38%+ lifts in persistence with this new knowledge). This experience can provide the pharma marketer with a needed guide to planning and program implementation.
At this month’s Center for Business Intelligence (CBI) Patient Adherence and Support Summit (April 29-30), in Philadelphia, brand directors and marketers will have a unique opportunity to hear senior VP’s, consultants and academic researchers provide their perspectives on what we know and need to target in 2013.
The event will begin with a keynote panel speaking about the changing DNA of patient adherence programs. Presenters will be VP’s and Senior Directors from Eli Lilly, GSK, Sanofi, and Shire.
For the first time since the inception of CBI’s Strategic Patient Adherence (SPA) Awards, there will be a look back at where the winning programs are today. This panel will follow presentation of an Adherence Roadmap by Dr. William Shrank, a prolific adherence researcher.
Tuesday will include a unique opportunity to hear one of the world’s most cited industry researchers, Merck’s Dr. Colleen McHorney. Dr. McHorney will be reviewing the history of adherence research and how the paradigm has shifted.
For more information on this event, now in its 12th year, go to:
http://www.cbinet.com/conference/pc13116#.UVx-3KLvHE0
For more information on this article, you can reach Grant Corbett, Principal, Behavior Change Solutions, Inc. at grant.corbett@behavior-change-solutions.com.
See also: http://blog.pharmexec.com/2013/03/12/changing-the-dna-of-pharma-patient-adherence-programs/
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.